2023 World Conference on Lung Cancer (Posters)-EP13.01. Validation of LIPI index in SCLC

Pdf Summary

This study aimed to validate the Neutrophil-Lymphocyte Ratio (NLR) and LDH levels as predictors of response to immunotherapy using the  Liquid-Index for Predicting Immunotherapy (LIPI) in small cell lung cancer (SCLC) patients. The study included 118 SCLC patients who received first-line treatment with the combination of atezolizumab and chemotherapy. The NLR was calculated at baseline and at the beginning of the third cycle, and LIPI was calculated based on NLR and LDH levels. The results showed that most patients had NLR and LDH levels within normal range. The LIPI index was distributed among the patients as follows: 45.9% LIPI 0, 43.9% LIPI 1, and 10.9% LIPI 2. However, there were no significant differences in prognosis between these three LIPI groups. Median overall survival (OS) was 12.5 months, and median progression-free survival (PFS) was 5 months. The NLR, LDH levels, and LIPI index did not have a significant impact on OS, but LIPI-0 group showed a better PFS compared to LIPI-1 and LIPI-2 groups. The study suggests that NLR, LDH levels, and LIPI index may not be reliable prognostic factors or predictors of response to chemoimmunotherapy in SCLC patients. However, the LIPI index could be a potential prognostic factor for PFS in SCLC patients and warrants further study in prospective research.

Asset Subtitle

Ruth Alvarez Cabellos

Meta Tag

Speaker Ruth Alvarez Cabellos

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

Neutrophil-Lymphocyte Ratio

LDH levels

immunotherapy

Liquid-Index for Predicting Immunotherapy

small cell lung cancer

SCLC

atezolizumab

chemotherapy

prognosis

LIPI index